BioMarin Pharmaceutical filed a report with the Securities and Exchange Commission on July 24, 2026.
3 reports, 1 independent
Updated Aug 18
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BioMarin Pharmaceutical filed a report with the Securities and Exchange Commission on July 24, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
BioMarin Pharmaceutical
American company
Nothing else this week.
-
Securities and Exchange Commission
government agency of the Philippines
Related events
- BioMarin Pharmaceutical and CollPlant Biotechnologies were listed on Nasdaq and are being compared as healthcare companies.
- BioMarin Pharmaceutical stock received updates on July 18, 2026, including a price target boost from Citigroup, reported by Benzinga.
- BioMarin Pharmaceutical filed a Form 13F with the SEC, coinciding with William Blair upgrading its stock rating.
- GT Biopharma filed with the SEC regarding institutional investment, and its stock traded on the Nasdaq exchange.
- Berto Acquisition Corp. filed a disclosure document with the Securities and Exchange Commission on November 11, 2026.